[Federal Register Volume 82, Number 165 (Monday, August 28, 2017)]
[Notices]
[Pages 40775-40776]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18137]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240-627-3705, 
<a href="/cdn-cgi/l/email-protection#5d1e352f342e7316322f333c361d333435733a322b"><span class="__cf_email__" data-cfemail="46052e342f35680d293428272d06282f2e68212930">[email protected]</span></a>. Licensing information and copies of the U.S. 
patent applications listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

HIV Targets CD62L on Central Memory T Cells Through Viral Envelope 
Glycans for Adhesion and Induces Selectin Shedding for Viral Release

Description of Technology

    Despite the success of anti-retroviral therapy in controlling HIV 
in infected individuals, treatment is less effective at eliminating HIV 
viral reservoirs. The nature of HIV reservoirs and the factors 
controlling their size and release are a major research focus for 
achieving a cure for HIV/AIDS.
    NIAID researchers have identified L-selectin/CD62L as a new target 
for treating HIV by inhibiting viral release from infected cells. They 
found that shedding of CD62L on T cells is required for the efficient 
release of HIV virus from infected cells. Further, they have shown that 
inhibition of CD62L shedding dramatically reduced HIV-1 infection and 
viral release from both viremic and aviremic CD4+ T cells. Therefore, 
inhibitors for CD62L sheddase can function as an anti-HIV treatment 
that may be effective alone or in combination with existing 
therapeutics.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

    <bullet> New target for HIV therapeutic development.

[[Page 40776]]

Competitive Advantages

    <bullet> This invention comprises a method of treating HIV using 
therapeutics geared toward viral release and entry, distinguishing it 
from other antiviral candidates with its method of action.
    <bullet> CD62L is a new target for HIV

Development Stage

    <bullet> In vitro studies; Proof-of-concept studies.

Inventors

Peter Sun, NIAID, NIH
Joseph Kononchik, NIAID, NIH
Joanna Ireland, NIAID, NIH
Ruiping Wang, NIAID, NIH

    Intellectual Property: HHS Reference No. E-261-2015/0--PCT No. PCT/
US2016/068713 filed 12/27/2016.
    Licensing Contact: Chris Kornak, 240-627-3705, 
<a href="/cdn-cgi/l/email-protection#1c5f746e756f3257736e727d775c727574327b736a"><span class="__cf_email__" data-cfemail="d695bea4bfa5f89db9a4b8b7bd96b8bfbef8b1b9a0">[email protected]</span></a>.
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further co-develop this technology by 
identifying pharmacological compounds inhibiting CD62L shedding by 
using high throughput compound screening. For collaboration 
opportunities, please contact Chris Kornak, 240-627-3705, 
<a href="/cdn-cgi/l/email-protection#7f3c170d160c5134100d111e143f11161751181009"><span class="__cf_email__" data-cfemail="9ddef5eff4eeb3d6f2eff3fcf6ddf3f4f5b3faf2eb">[email protected]</span></a>.

    Dated: August 15, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-18137 Filed 8-25-17; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>